Garetosmab

加托索单抗

Report date: 2026/05/06 20:02:28

Base Information

Drug NameGaretosmab
Drug Alias NameREGN-2477R2477
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionInhibin beta A chain inhibitors
TargetsInhibin beta A chain
Therapy Area/IndicationsOssification, HeterotopicObesityMyositis Ossificans +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[22] 
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesRegeneron Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesRegeneron Pharmaceuticals IncBeijing Kendlewits Medical Consulting Co Ltd
Inactive CompaniesN/A
Active IndicationsObesityMyositis Ossificans
Inactive IndicationsOssification, HeterotopicMyositis, Inclusion Body

Other Information

ATC CodeN/A
Related LinksN/A